Rituximab, a CD20-specific monoclonal antibody that depletes B cells, has shown promising results in patients with relapsing-remitting multiple sclerosis. Studies of experimental autoimmune ...

"The most significant finding here is the confirmation that our B-cell therapies not only can activate tumor-killing CD8 T cells, but a subset of them can infiltrate the tumor and produce ...

Completes Transition to Immune-Mediated Disease Focused CompanyHighlights Additional Data from Phase 1b Primary Membranous ...

Findings suggest the potential for obe-cel treatment without the need for consolidative SCTObe-cel given as a sole treatment to patients with ...

MicroRNAs control the activity of many key genes but were unknown before 1993.

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension ...

Fever temperatures rev up immune cell metabolism, proliferation and activity, but they also—in a particular subset of T cells—cause mitochondrial stress, DNA damage and cell death, Vanderbilt ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

By Pooja Toshniwal Paharia Study reveals that moderate fever temperatures (39°C) improve metabolism, proliferation, and ...

By Susha Cheriyedath, M.Sc. Researchers discover a novel protein therapy that recharges exhausted T cells, unleashing their ...

This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...